Loading publications…
The last 5 uploaded publications
Immune-inflammatory and hypothalamic-pituitary-adrenal axis biomarkers are altered in patients with non-specific low back pain: A systematic review
Juan P. Sanabria‐Mazo, Ariadna Colomer‐Carbonell, Meritxell Carmona-Cervelló, Albert Feliu‐Soler, Xavier Borrás, Mar Grasa, Montserrat Esteve, Michael Maes, Sílvia Edo, Antoni Sanz, Juan V. Luciano (2022). Immune-inflammatory and hypothalamic-pituitary-adrenal axis biomarkers are altered in patients with non-specific low back pain: A systematic review. , 13, DOI: https://doi.org/10.3389/fimmu.2022.945513.
Article50 days agoEffectiveness, cost-utility and physiological underpinnings of the FIBROWALK multicomponent therapy in online and outdoor format in individuals with fibromyalgia: Study protocol of a randomized, controlled trial (On&Out study)
Mayte Serrat, Sònia Ferrés, William Auer, Míriam Almirall, Enrique Lluch, Francesco D’Amico, Michael Maes, Sònia Lorente, Jaime Navarrete, Jesús Montero‐Marín, Randy Neblett, Jo Nijs, Xavier Borrás, Juan V. Luciano, Albert Feliu‐Soler (2022). Effectiveness, cost-utility and physiological underpinnings of the FIBROWALK multicomponent therapy in online and outdoor format in individuals with fibromyalgia: Study protocol of a randomized, controlled trial (On&Out study). , 13, DOI: https://doi.org/10.3389/fphys.2022.1046613.
Article50 days agoStudy protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
Ariadna Colomer‐Carbonell, Juan P. Sanabria‐Mazo, Halbert Hernández-Negrín, Xavier Borrás, Carlos Suso‐Ribera, Azucena García‐Palacios, Jordi Muchart, Josep Munuera, Francesco D’Amico, Michael Maes, Jarred Younger, Albert Feliu‐Soler, Antoni Rozadilla‐Sacanell, Juan V. Luciano (2022). Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). , 12(1), DOI: https://doi.org/10.1136/bmjopen-2021-055351.
Article50 days agoImmune-inflammatory pathways and clinical changes in fibromyalgia patients treated with Mindfulness-Based Stress Reduction (MBSR): A randomized, controlled clinical trial
Laura Andrés‐Rodríguez, Xavier Borrás, Albert Feliu‐Soler, Adrián Pérez‐Aranda, Antoni Rozadilla‐Sacanell, Jesús Montero‐Marín, Michael Maes, Juan V. Luciano (2019). Immune-inflammatory pathways and clinical changes in fibromyalgia patients treated with Mindfulness-Based Stress Reduction (MBSR): A randomized, controlled clinical trial. , 80, DOI: https://doi.org/10.1016/j.bbi.2019.02.030.
Article50 days agoEfficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study)
Juan P. Sanabria‐Mazo, Carlos G. Forero, Paula Cristóbal-Narváez, Carlos Suso‐Ribera, Azucena García‐Palacios, Ariadna Colomer‐Carbonell, Adrián Pérez‐Aranda, Laura Andrés‐Rodríguez, Lance M. McCracken, Francesco D’Amico, Pere Estivill-Rodríguez, Bernat Carreras-Marcos, Antonio Montes-Pérez, Olga Comps-Vicente, Montserrat Esteve, Mar Grasa, Araceli Rosa, Antonio Cuesta‐Vargas, Michael Maes, Xavier Borrás, Sílvia Edo, Antoni Sanz, Albert Feliu‐Soler, Juan R. Castaño-Asins, Juan V. Luciano (2020). Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study). , 10(7), DOI: https://doi.org/10.1136/bmjopen-2020-038107.
Article50 days ago